Jaa Roberson
Human Resources Officer chez DAY ONE BIOPHARMACEUTICALS, INC.
Profil
Jaa Roberson is currently the Chief People Officer at Day One Biopharmaceuticals, Inc. Prior to this, she worked as the Head of Human Resources at Achaogen, Inc. and as the Vice President of Human Resources at Bellicum Pharmaceuticals, Inc. from 2018 to 2020.
Ms. Roberson has an undergraduate degree from Rice University and a graduate degree from the San Francisco Conservatory of Music.
Postes actifs de Jaa Roberson
| Sociétés | Poste | Début |
|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Human Resources Officer | 13/09/2021 |
Anciens postes connus de Jaa Roberson
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Human Resources Officer | 01/11/2020 |
| ACHAOGEN | Human Resources Officer | - |
Formation de Jaa Roberson
| Rice University | Undergraduate Degree |
| San Francisco Conservatory of Music | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
